I call attention to this paper of mine just published in Eye & Contact Lens together with colleagues Drs. Kathryn Richdale, Erin Tomiyama and Mark Bullimore – a survey of the variability of atropine formulation, sterility and stability testing and storage requirements for compounded low dose atropine for myopia prevention. https://pubmed.ncbi.nlm.nih.gov/36083169/
Gary D. Novack, Ph..D. was honored by the American Academy of Ophthalmology (AAO). In the AAO’s honors for its 2022 Annual Meeting, Dr. Novack was cited by its Secretariat for his work on the Academy’s journal, Ophthalmology Glaucoma. Dr. Novack serves as both an author and reviewer for this journal.
Dr. Gary Novack presented an invited talk on “Why are there not more new glaucoma drugs” at the August meeting of the Glaucoma Research Society. The Glaucoma Research Society is a public interest, non-profit scientific association of outstanding glaucoma researchers that provides a forum to discuss and stimulate compelling or innovative research to prevent glaucoma-related […]
In May, Dr. Novack was part of a UC Davis Department of Ophthalmology & Vision Science weekend Continuing Medical Education course in Napa. He presented issues surrounding off-label use and compounded medications in ophthalmology. He also discussed generic vs. branded products.
Dr. Novack, served as a judge at the UC Davis Department of Ophthalmology & Visual Sciences annual trainee and alumni research day. It was a great day highlighting the quality of our trainees, faculty, alumni and guest speaker, George B. Bartley , M.D.
Dr. Novack was featured in a spotlight on ARVO members in a May 2022 posting of The Ophthalmologist entitled “Captain’s Log”, the reported focused on Dr. Novack’s answer to a query about an analogy for his work. Novack said “…like Captain James T. Kirk in the Star Trek Original Series “Corbomite Maneuver”, episode, I use […]
Dr. Gary Novack presented two posters at the May 2022 ARVO conference in Denver. One of these was presented in the Cornea section on preclinical data on a new investigative potential treatment for dry eye disease. The other was presented in the retina section on Phase 3 studies of a new topical anesthetic for use […]
With a recent product approval, Dr. Novack has now made substantial contributions to 60 approved products during his career…
PharmaLogic Development, Inc. has been contracted to provide service to Zhaoke Ophthalmology Limited in their ophthalmic product development…
In a recent article in JAMA Oncology on the use of surrogate endpoints in oncology, del Paggio et al identified industry funding for nearly all. They further highlighted the use of medical writers in papers published on this work to be of concern…